瓦达司他对比达依泊汀α治疗日本血透贫血患者的3期随机双盲研究
本研究为3期多中心随机双盲试验,将323例接受ESA治疗的日本血透贫血患者切换为口服瓦达司他或达依泊汀α治疗52周,调整剂量维持Hb 10.0-12.0 g/dL。主要终点20周和24周平均Hb水平显示瓦达司他不劣于达依泊汀α(差值-0.05 g/dL,95%CI -0.26至0.17),安全性与对照组相似。
要点
- 瓦达司他20/24周平均Hb非劣于达依泊汀α,差值-0.05 g/dL。
- 两组Hb在52周内均维持在10.0-12.0 g/dL目标范围内。
- 常见不良事件两组频率相似,未发现新的安全性信号。
核心结论
- 瓦达司他在维持日本血透贫血患者Hb目标范围方面不劣于达依泊汀α,且耐受性良好。
- 瓦达司他可成为接受ESA治疗的血透贫血患者的替代选择。
研究设计与样本
- 3期、多中心、随机、双盲研究,纳入323例接受ESA治疗的日本血透贫血患者。
- 患者随机切换至瓦达司他或达依泊汀α治疗52周,调整剂量维持Hb 10.0-12.0 g/dL。
- 主要终点为第20周和第24周的平均Hb水平。
主要发现
- 第20周和第24周平均Hb(LSM及95%CI)瓦达司他组为10.61(10.45-10.76)g/dL,达依泊汀α组为10.65(10.50-10.80)g/dL。
- 差值-0.05 g/dL(95%CI -0.26至0.17),证明瓦达司他不劣于达依泊汀α。
- 两组52周内平均Hb均维持在目标范围,且无论患者背景如何,第52周Hb的LSM均在目标范围内。
- 最常见不良事件为鼻咽炎、腹泻和分流道狭窄,两组发生频率相似,未发现新的安全性问题。
临床怎么用
- 对于接受ESA治疗的血透贫血患者,可考虑切换至口服瓦达司他维持Hb在10.0-12.0 g/dL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHODS: The efficacy and safety of vadadustat, compared with darbepoetin alfa, was determined in a Phase 3 double-blind study in Japanese anemic patients on hemodialysis. Patients receiving erythropoiesis-stimulating agents (ESAs) were randomized and switched to either vadadustat or darbepoetin alfa for 52 weeks. Doses were adjusted to maintain a hemoglobin (Hb) level of 10.0-12.0 g/dL. The primary endpoint was average Hb level at Weeks 20 and 24. RESULTS: Of the 323 randomized patients, 120 and 135 completed the 52-week treatment period in the vadadustat and darbepoetin alfa groups, respectively. The average Hb levels at Weeks 20 and 24 [least square mean (LSM) and 95% confidence interval (CI)] were 10.61 (10.45-10.76) and 10.65 (10.50-10.80) g/dL in the vadadustat and darbepoetin alfa groups, respectively, demonstrating vadadustat's noninferiority to darbepoetin alfa (difference: -0.05 g/dL; 95% CI -0.26 to 0.17). In both groups, the mean Hb levels were maintained within the target range for 52 weeks. Furthermore, irrespective of patient backgrounds, the LSMs of Hb at Week 52 were within the target range. The most common adverse events were nasopharyngitis, diarrhea and shunt stenosis, which occurred at similar frequencies in both groups. No new safety concerns were identified. CONCLUSIONS: Vadadustat was as well-tolerated and effective as darbepoetin alfa in maintaining Hb levels within the target range. The findings suggest that vadadustat can be an alternative to ESA in the management of anemia in Japanese hemodialysis patients receiving ESA (ClinicalTrials.gov, NCT03439137).
引用
- Nangaku M, Kondo K, Ueta K, et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant. 2021. PMID: 33650630. doi:10.1093/ndt/gfab055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。